{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Nashville&page=3&state=Tennessee",
    "query": {
      "state": "Tennessee",
      "city": "Nashville",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 10857,
    "total_pages": 1086,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Nashville&page=4&state=Tennessee&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Nashville&page=2&state=Tennessee&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T16:45:27.946Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03709771",
      "title": "Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Renal Cell Carcinoma",
        "Hypertension",
        "Melanoma",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Ambulatory Blood Pressure Measurement",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 2,
      "start_date": "2020-01-09",
      "completion_date": "2020-10-01",
      "has_results": true,
      "last_update_posted_date": "2024-01-12",
      "last_synced_at": "2026-10-31T16:45:27.946Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03709771"
    },
    {
      "nct_id": "NCT05501704",
      "title": "ETHAN - ET for Male BC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Male Breast Cancer",
        "Hormone Receptor-positive Breast Cancer",
        "Hormone Receptor Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Degarelix",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jose Pablo Leone",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2023-10-11",
      "completion_date": "2036-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-10-31T16:45:27.946Z",
      "location_count": 9,
      "location_summary": "Washington D.C., District of Columbia • Jacksonville, Florida • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05501704"
    },
    {
      "nct_id": "NCT02335749",
      "title": "CoolSculpting of the Distal Thigh Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Body Fat Disorder"
      ],
      "interventions": [
        {
          "name": "The ZELTIQ System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Zeltiq Aesthetics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "22 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2014-12-17",
      "completion_date": "2015-11-09",
      "has_results": true,
      "last_update_posted_date": "2021-12-01",
      "last_synced_at": "2026-10-31T16:45:27.946Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Chestnut Hill, Massachusetts • New York, New York + 1 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chestnut Hill",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02335749"
    },
    {
      "nct_id": "NCT06854458",
      "title": "The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ischemic Heart Disease (IHD)",
        "Cardiac Magnetic Resonance Imaging",
        "Myocardial Blood Flow"
      ],
      "interventions": [
        {
          "name": "Quantitative Myocardial Blood Flow Evaluation",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Qualitative Myocardial Blood Flow Evaluation",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Gadavist",
          "type": "DRUG"
        },
        {
          "name": "Vasodilator",
          "type": "DRUG"
        },
        {
          "name": "Blood draw for the laboratory assessment",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "35 Years to 85 Years"
      },
      "enrollment_count": 1000,
      "start_date": "2025-06-27",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-31T16:45:27.946Z",
      "location_count": 13,
      "location_summary": "San Francisco, California • Louisville, Kentucky • Boston, Massachusetts + 9 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Roslyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06854458"
    },
    {
      "nct_id": "NCT03449030",
      "title": "A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies"
      ],
      "interventions": [
        {
          "name": "TAK-164",
          "type": "DRUG"
        },
        {
          "name": "89Zr-TAK-164",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2018-04-23",
      "completion_date": "2020-02-27",
      "has_results": true,
      "last_update_posted_date": "2021-03-22",
      "last_synced_at": "2026-10-31T16:45:27.946Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Tampa, Florida • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03449030"
    },
    {
      "nct_id": "NCT01951664",
      "title": "Feasibility and Preliminary Efficacy of Hatha Yoga in Head and Neck Cancer Survivors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Head Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Baseline Study Measures",
          "type": "OTHER"
        },
        {
          "name": "Yoga Evaluation",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Yoga Program",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Yoga Practice Plan",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Study Assessments",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2013-08",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2016-04-27",
      "last_synced_at": "2026-10-31T16:45:27.946Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01951664"
    },
    {
      "nct_id": "NCT00592709",
      "title": "Analysis of Brain Tumors Using Matrix Assisted Laser Desorption/Ionization Mass Spectrometry",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Brain Diseases"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "2 Years to 85 Years"
      },
      "enrollment_count": 84,
      "start_date": "2003-05",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2021-02-21",
      "last_synced_at": "2026-10-31T16:45:27.946Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00592709"
    },
    {
      "nct_id": "NCT03948763",
      "title": "A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Pancreatic Neoplasms",
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "V941",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2019-06-26",
      "completion_date": "2022-08-25",
      "has_results": true,
      "last_update_posted_date": "2025-01-28",
      "last_synced_at": "2026-10-31T16:45:27.946Z",
      "location_count": 10,
      "location_summary": "Gilbert, Arizona • Duarte, California • San Francisco, California + 7 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03948763"
    },
    {
      "nct_id": "NCT01055314",
      "title": "Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Rhabdomyosarcoma",
        "Childhood Alveolar Rhabdomyosarcoma",
        "Childhood Embryonal Rhabdomyosarcoma",
        "Metastatic Childhood Soft Tissue Sarcoma",
        "Stage IV Adult Soft Tissue Sarcoma",
        "Untreated Childhood Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Cixutumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Dactinomycin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate Liposome",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "Up to 49 Years"
      },
      "enrollment_count": 175,
      "start_date": "2010-01",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2017-08-29",
      "last_synced_at": "2026-10-31T16:45:27.946Z",
      "location_count": 121,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01055314"
    },
    {
      "nct_id": "NCT05735184",
      "title": "A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Mixed Lineage Leukemia Gene Mutation",
        "Refractory AML",
        "AML With Mutated NPM1",
        "Acute Myeloid Leukemia Recurrent",
        "Acute Myeloid Leukemia, in Relapse",
        "NPM1 Mutation",
        "KMT2Ar",
        "Myeloid Sarcoma",
        "Nucleophosmin 1-mutated Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Ziftomenib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Quizartinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kura Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 420,
      "start_date": "2023-07-18",
      "completion_date": "2030-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-10-31T16:45:27.946Z",
      "location_count": 44,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 36 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05735184"
    }
  ]
}